Add like
Add dislike
Add to saved papers

Treatment of scapholunate dissociation by ligamentous repair and capsulodesis.

We believe that direct scapholunate ligamentous repair, supported by a dorsal radioscaphoid capsulodesis, should be considered for the treatment of most scapholunate dissociations when there is no osteoarthritis, regardless of the time that has elapsed since injury. We treated 24 patients by this technique between 1972 and 1988. The records of 21 were available for study. Average time from injury to surgical treatment was 17 months (range, 1 to 84 months). Results were evaluated clinically and by means of patient questionnaire and x-ray films. The significant change in range of motion was a loss of palmar flexion, which averaged 11.5 degrees. Grip strength, pain, and x-ray appearance improved in all cases. Only one patient had to change occupations after surgery because of wrist symptoms. Three had minimal x-ray degenerative changes, which did not result in increased pain or in loss of motion and grip strength. There were no complications.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app